CD33 reponses are blocked by SOCS3 through accelerated proteasomal-mediated turnover

Christopher Scott, S.J. Orr, James Johnston, N.M. Morgan, Joanne Elliott, James Burrows, D.W. McVickar

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

CD33 is a member of the sialic acid–binding immunoglobulin-like lectin (Siglec) family of inhibitory receptors and a therapeutic target for acute myeloid leukemia (AML). CD33 contains a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), which can recruit SHP-1 and SHP-2. How CD33 expression is regulated is unclear. Suppressor of cytokine signaling 3 (SOCS3) is expressed in response to cytokines, LPS, and other PAMPs, and competes with SHP-1/2 binding to ITIMs of cytokine receptors, thereby inhibiting signaling. In this study, using peptide pull-down experiments, we found that SOCS3 can specifically bind to the phosphorylated ITIM of CD33. Additionally, following cross-linking SOCS3 can recruit the ECS E3 ligase resulting in accelerated proteasomal degradation of both CD33 and SOCS3. Our data suggest that the tyrosine motifs in CD33 are not important for internalization, while they are required for degradation. Moreover, SOCS3 inhibited the CD33-induced block on cytokine-induced proliferation. This is the first receptor shown to be degraded by SOCS3 and where SOCS3 and its target protein are degraded concomitantly. Our findings clearly suggest that during an inflammatory response, the inhibitory receptor CD33 is lost by this mechanism. Moreover, this has important clinical implications as tumors expressing SOCS3 may be refractory to -CD33 therapy.
LanguageEnglish
Pages1061-1068
Number of pages8
JournalBlood
Volume109(3)
Issue number3
DOIs
Publication statusPublished - 01 Feb 2007

Fingerprint

Cytokines
Tyrosine
Sialic Acid Binding Immunoglobulin-like Lectins
Degradation
Cytokine Receptors
Ubiquitin-Protein Ligases
Acute Myeloid Leukemia
Refractory materials
Tumors
Peptides
Therapeutics
Neoplasms
Proteins
Experiments

Cite this

Scott, C., Orr, S. J., Johnston, J., Morgan, N. M., Elliott, J., Burrows, J., & McVickar, D. W. (2007). CD33 reponses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood, 109(3)(3), 1061-1068. https://doi.org/10.1182/blood-2006-05-023556
Scott, Christopher ; Orr, S.J. ; Johnston, James ; Morgan, N.M. ; Elliott, Joanne ; Burrows, James ; McVickar, D.W. / CD33 reponses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. In: Blood. 2007 ; Vol. 109(3), No. 3. pp. 1061-1068.
@article{7db76bd6a7b94c88a501ab7808f579f3,
title = "CD33 reponses are blocked by SOCS3 through accelerated proteasomal-mediated turnover",
abstract = "CD33 is a member of the sialic acid–binding immunoglobulin-like lectin (Siglec) family of inhibitory receptors and a therapeutic target for acute myeloid leukemia (AML). CD33 contains a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), which can recruit SHP-1 and SHP-2. How CD33 expression is regulated is unclear. Suppressor of cytokine signaling 3 (SOCS3) is expressed in response to cytokines, LPS, and other PAMPs, and competes with SHP-1/2 binding to ITIMs of cytokine receptors, thereby inhibiting signaling. In this study, using peptide pull-down experiments, we found that SOCS3 can specifically bind to the phosphorylated ITIM of CD33. Additionally, following cross-linking SOCS3 can recruit the ECS E3 ligase resulting in accelerated proteasomal degradation of both CD33 and SOCS3. Our data suggest that the tyrosine motifs in CD33 are not important for internalization, while they are required for degradation. Moreover, SOCS3 inhibited the CD33-induced block on cytokine-induced proliferation. This is the first receptor shown to be degraded by SOCS3 and where SOCS3 and its target protein are degraded concomitantly. Our findings clearly suggest that during an inflammatory response, the inhibitory receptor CD33 is lost by this mechanism. Moreover, this has important clinical implications as tumors expressing SOCS3 may be refractory to -CD33 therapy.",
author = "Christopher Scott and S.J. Orr and James Johnston and N.M. Morgan and Joanne Elliott and James Burrows and D.W. McVickar",
year = "2007",
month = "2",
day = "1",
doi = "10.1182/blood-2006-05-023556",
language = "English",
volume = "109(3)",
pages = "1061--1068",
journal = "Blood",
issn = "0006-4971",
publisher = "AMER SOC HEMATOLOGY",
number = "3",

}

Scott, C, Orr, SJ, Johnston, J, Morgan, NM, Elliott, J, Burrows, J & McVickar, DW 2007, 'CD33 reponses are blocked by SOCS3 through accelerated proteasomal-mediated turnover', Blood, vol. 109(3), no. 3, pp. 1061-1068. https://doi.org/10.1182/blood-2006-05-023556

CD33 reponses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. / Scott, Christopher; Orr, S.J.; Johnston, James; Morgan, N.M.; Elliott, Joanne; Burrows, James; McVickar, D.W.

In: Blood, Vol. 109(3), No. 3, 01.02.2007, p. 1061-1068.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CD33 reponses are blocked by SOCS3 through accelerated proteasomal-mediated turnover

AU - Scott, Christopher

AU - Orr, S.J.

AU - Johnston, James

AU - Morgan, N.M.

AU - Elliott, Joanne

AU - Burrows, James

AU - McVickar, D.W.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - CD33 is a member of the sialic acid–binding immunoglobulin-like lectin (Siglec) family of inhibitory receptors and a therapeutic target for acute myeloid leukemia (AML). CD33 contains a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), which can recruit SHP-1 and SHP-2. How CD33 expression is regulated is unclear. Suppressor of cytokine signaling 3 (SOCS3) is expressed in response to cytokines, LPS, and other PAMPs, and competes with SHP-1/2 binding to ITIMs of cytokine receptors, thereby inhibiting signaling. In this study, using peptide pull-down experiments, we found that SOCS3 can specifically bind to the phosphorylated ITIM of CD33. Additionally, following cross-linking SOCS3 can recruit the ECS E3 ligase resulting in accelerated proteasomal degradation of both CD33 and SOCS3. Our data suggest that the tyrosine motifs in CD33 are not important for internalization, while they are required for degradation. Moreover, SOCS3 inhibited the CD33-induced block on cytokine-induced proliferation. This is the first receptor shown to be degraded by SOCS3 and where SOCS3 and its target protein are degraded concomitantly. Our findings clearly suggest that during an inflammatory response, the inhibitory receptor CD33 is lost by this mechanism. Moreover, this has important clinical implications as tumors expressing SOCS3 may be refractory to -CD33 therapy.

AB - CD33 is a member of the sialic acid–binding immunoglobulin-like lectin (Siglec) family of inhibitory receptors and a therapeutic target for acute myeloid leukemia (AML). CD33 contains a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), which can recruit SHP-1 and SHP-2. How CD33 expression is regulated is unclear. Suppressor of cytokine signaling 3 (SOCS3) is expressed in response to cytokines, LPS, and other PAMPs, and competes with SHP-1/2 binding to ITIMs of cytokine receptors, thereby inhibiting signaling. In this study, using peptide pull-down experiments, we found that SOCS3 can specifically bind to the phosphorylated ITIM of CD33. Additionally, following cross-linking SOCS3 can recruit the ECS E3 ligase resulting in accelerated proteasomal degradation of both CD33 and SOCS3. Our data suggest that the tyrosine motifs in CD33 are not important for internalization, while they are required for degradation. Moreover, SOCS3 inhibited the CD33-induced block on cytokine-induced proliferation. This is the first receptor shown to be degraded by SOCS3 and where SOCS3 and its target protein are degraded concomitantly. Our findings clearly suggest that during an inflammatory response, the inhibitory receptor CD33 is lost by this mechanism. Moreover, this has important clinical implications as tumors expressing SOCS3 may be refractory to -CD33 therapy.

UR - http://www.scopus.com/inward/record.url?scp=33846864687&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-05-023556

DO - 10.1182/blood-2006-05-023556

M3 - Article

VL - 109(3)

SP - 1061

EP - 1068

JO - Blood

T2 - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -